Avita Therapeutics (AVH.AU) saw its stock soar 5.26% in Tuesday's trading session following the release of promising data for its Recell system. The surge came after researchers presented findings at the annual meeting of the British Burn Association, demonstrating significant benefits for burn patients treated with the company's innovative technology.

The study, described as the largest real-world analysis of skin cell suspension autograft to date, examined registry data from over 6,300 patients treated with Recell between 2019 and 2024. For patients with burns covering less than 30% of their total body surface area, treatment with Recell Spray-On Skin Cells alone reduced hospital stays by an average of 6.2 days, or about 36%, compared to patients treated with traditional split-thickness autografts. This reduction in hospital stays translated to substantial cost savings, estimated at around AU$300 million over the five-year study period.

The positive results from this large-scale study could potentially boost the adoption of Avita's Recell system in burn treatment centers worldwide. As healthcare providers increasingly prioritize both patient outcomes and cost-effectiveness, the demonstrated benefits of reduced hospital stays and significant cost savings may drive greater demand for Avita's technology. Investors appear to be reacting positively to the implications of this data for the company's future growth prospects and market position in the burn treatment sector.